Healthcare Active Stocks: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Pfizer Inc. (NYSE:PFE)’s chief executive acknowledged Tuesday that a potential merger with AstraZeneca would lead to job losses, but promised to keep key research jobs in Britain as part of its $106 billion takeover bid. Pfizer Inc. (NYSE:PFE) stock performance was 0.24% in last session and finished the day at $29.20. Traded volume was 26.29million shares in the last session and the average volume of … Continue reading Healthcare Active Stocks: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Hot Biotech Movers: MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences, Inc. (NASDAQ:GILD), Chelsea Therapeutics (NASDAQ:CHTP)

MannKind Corporation (NASDAQ:MNKD) loss of 14 cents per share in the first quarter of 2014 was wider than the Zacks Consensus Estimate by a penny but narrower than the year-ago loss by a penny. MannKind Corporation (NASDAQ:MNKD) did not generate any revenue in the first quarter of 2014, as in the year-ago quarter. Research and development (R&D) expenses remained flat at $26.2 million in the … Continue reading Hot Biotech Movers: MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences, Inc. (NASDAQ:GILD), Chelsea Therapeutics (NASDAQ:CHTP)

Hot Biotech Movers: VIVUS (NASDAQ:VVUS), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA)

VIVUS Inc (NASDAQ:VVUS) will be announcing its Q114 earnings results on Monday, May 5th. Analysts expect the company to announce earnings of ($0.37) per share and revenue of $11.40 million for the quarter. VIVUS, Inc. (NASDAQ:VVUS) stock performance was -2.12% in last session and finished the day at $5.09. Traded volume was 1.34million shares in the last session and the average volume of the stock … Continue reading Hot Biotech Movers: VIVUS (NASDAQ:VVUS), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA)

Healthcare Most Active Stocks: Teva Pharmaceutical Industries (NYSE:TEVA), Johnson & Johnson (NYSE:JNJ), MannKind Corporation (NASDAQ:MNKD), Abbott Laboratories (NYSE:ABT)

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) is one of half a dozen drugmakers that have been rolling out generics of Eli Lilly’s ($LLY) top-selling blockbuster Cymbalta. The others are going to roll past the Israeli drugmaker after it recalled more than 1 million bottles of the antidepressant. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock performance was -0.76% in last session and finished the day at … Continue reading Healthcare Most Active Stocks: Teva Pharmaceutical Industries (NYSE:TEVA), Johnson & Johnson (NYSE:JNJ), MannKind Corporation (NASDAQ:MNKD), Abbott Laboratories (NYSE:ABT)

Health Stocks In New: Amgen (NASDAQ:AMGN), Novavax (NASDAQ:NVAX), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Amgen Inc. (NASDAQ:AMGN) carries a Zacks Rank #1 (Strong Buy). Amgen, Inc. (NASDAQ:AMGN) stock performance was -1.90% in last session and finished the day at $111.94. Traded volume was 7.26million shares in the last session and the average volume of the stock remained 3.63million shares. The beta of the stock remained 0.51. Amgen, Inc. (NASDAQ:AMGN) insider ownership is 0.10%. Novavax, Inc. (NASDAQ:NVAX), a clinical-stage biopharmaceutical … Continue reading Health Stocks In New: Amgen (NASDAQ:AMGN), Novavax (NASDAQ:NVAX), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Gilead Sciences GILD NASDAQ:GILD

Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)

MannKind Corporation (NASDAQ:MNKD) announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA(R) by three months to July 15, 2014 in order to provide time for a full review of information submitted by MannKind in response to the FDA’s requests.MannKind Corporation (NASDAQ:MNKD) stock performance was -6.42% in last session and finished the day at … Continue reading Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)